Clinical Trial Update: De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

View source ↗

Summary

This clinical trial update discusses de novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Severance Hospital | Conditions: NSCLC | Status: UNKNOWN